文献速递神经介入DSA

机械取栓的当代结果及一线技术对结局的影响:INSPIRE-S全球登记研究

Contemporary Results of Mechanical Thrombectomy and Impact of First-Line Technique on Outcome: The INSPIRE-S Global Registry.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-11-03

INSPIRE-S为前瞻性、影像核心实验室裁定的全球登记研究,纳入802例急性缺血性卒中患者,按一线机械取栓技术分为支架取栓器组259例、单纯抽吸组146例和联合治疗组397例;三组90天良好临床结局、首次再通率及最终完全再灌注率均无显著差异,症状性颅内出血1.5%、全因死亡14.0%组间亦无显著差异。

要点

  • 三组90天良好临床结局无显著差异:支架取栓器组60.5%、单纯抽吸组52.8%、联合治疗组56.6%。
  • 三组首次再通率无显著差异:支架取栓器组48.6%、单纯抽吸组39.9%、联合治疗组47.5%。
  • 按闭塞部位亚组分析,颈内动脉闭塞中单纯抽吸组首次再通率最低(P=0.003)。

核心结论

  • 真实世界数据显示,三种一线机械取栓技术的首次完全再通率整体较高,最终临床结局相似,全因死亡(14.0%)和症状性颅内出血(1.5%)组间无显著差异。

研究设计与样本

  • INSPIRE-S为前瞻性、影像核心实验室裁定、安全临床事件委员会裁定的全球登记研究,2020年5月至2022年12月纳入802例符合标准的急性缺血性卒中患者(29个中心、13个国家),首过使用美敦力神经血管器械并按一线取栓技术分组:支架取栓器组259例、单纯抽吸组146例、联合治疗组397例;影像核心实验室裁定再灌注分级,临床事件委员会裁定安全事件。

关键影像表现/征象

  • 大脑中动脉M1/M2段闭塞占76.1%,平均取栓次数为1.9±1.3次。
  • 支架取栓器组、单纯抽吸组和联合治疗组的首次再通率分别为48.6%、39.9%和47.5%(P>0.05)。
  • 支架取栓器组、单纯抽吸组和联合治疗组的最终完全再灌注(eTICI≥2c)率分别为77.4%、70.6%和72.0%(校正分析P>0.05)。

诊断标准与关键数值

  • 首次再通定义为expanded TICI(eTICI)≥2c。
  • 良好临床结局定义为90天mRS≤2或恢复至卒中前mRS。
  • 最终完全再灌注定义为eTICI≥2c。
  • 症状性颅内出血由临床事件委员会裁定,总体发生率为1.5%。
  • 全因死亡由临床事件委员会裁定,总体发生率为14.0%。

临床应用与阅片要点

  • 原文结论指出三种一线技术最终临床结局相似,未给出具体的术式推荐。
  • 按闭塞部位亚组分析显示,颈内动脉闭塞中单纯抽吸组首次再通率最低(P=0.003),单纯抽吸组用于颈内动脉闭塞的比例高于支架取栓器组(P=0.03)。
  • 当患者采用中心首选技术治疗时,各技术间首次再通率无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Three mechanical thrombectomy (MT) techniques are predominantly used for the treatment of acute ischemic stroke (AIS): stent retriever only (SR), aspiration only (ASP), and combination therapy (CT) with a general goal of achieving first-pass reperfusion (FPR; expanded TICI [eTICI] ≥ 2c). Factors influencing FPR and the relative efficacy and safety of the 3 techniques are loosely understood.

MATERIALS AND METHODS: The Innovative Neurovascular Product Surveillance Registry (INSPIRE-S) is a prospective, imaging core-lab-adjudicated, safety clinical events committee-adjudicated, global registry of patients with AIS treated with Medtronic neurovascular devices on the first pass and grouped according to first-pass MT technique.

RESULTS: From May 2020 through December 2022, 802 patients (29 sites, 13 countries) who met eligibility criteria were enrolled in the INSPIRE-S registry and were grouped by first-pass MT technique (259 in SR, 146 in ASP, and 397 in CT). Overall, MCA-M1/M2 occlusions were present in 76.1% of patients, and the mean number of passes was 1.9 ± 1.3. Among the techniques, the primary end point, good clinical outcome (mRS ≤ 2 or return to prestroke mRS) at 90 days was achieved in 60.5% in SR, 52.8% in ASP, and 56.6% in CT (P > .05 in unadjusted and adjusted analyses). The FPR rates were 48.6% in SR, 39.9% in ASP, and 47.5% in CT (P > .05), and final complete (eTICI ≥ 2c) reperfusion rates were 77.4% in SR, 70.6% in ASP, and 72.0% in CT (P > .05 in adjusted analyses). In subgroup analyses by occlusion location, ASP had the lowest FPR in the ICA (P = .003), while ASP was more frequently employed than SR for ICA (P = .03). There was no significant difference in FPR among techniques when patients were treated with site-preferred technique. The overall rates of Clinical Events Committee-adjudicated all-cause mortality (14.0%) and symptomatic intracranial hemorrhage (1.5%) did not significantly differ among the techniques.

CONCLUSIONS: The primary results of real-world data from INSPIRE-S showed overall high rates of first-pass complete reperfusion and final clinical outcomes that were similar among the 3 MT techniques.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Rodrigo-Gisbert M, Ribo M, Möhlenbruch M, et al. Contemporary Results of Mechanical Thrombectomy and Impact of First-Line Technique on Outcome: The INSPIRE-S Global Registry. AJNR Am J Neuroradiol. 2025. PMID: 40506228. doi:10.3174/ajnr.A8848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。